Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 677,654
  • Shares Outstanding, K 30,429
  • Annual Sales, $ 17,160 K
  • Annual Income, $ -163,620 K
  • EBIT $ -140 M
  • EBITDA $ -148 M
  • 60-Month Beta -0.24
  • Price/Sales 37.55
  • Price/Cash Flow N/A
  • Price/Book 7.64

Options Overview Details

View History
  • Implied Volatility 278.59% ( -6.84%)
  • Historical Volatility 114.16%
  • IV Percentile 97%
  • IV Rank 96.70%
  • IV High 286.36% on 11/19/24
  • IV Low 50.66% on 11/24/23
  • Put/Call Vol Ratio 1.24
  • Today's Volume 132
  • Volume Avg (30-Day) 1,749
  • Put/Call OI Ratio 1.54
  • Today's Open Interest 42,313
  • Open Int (30-Day) 37,417

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.56
  • Number of Estimates 8
  • High Estimate -0.81
  • Low Estimate -1.84
  • Prior Year -1.59
  • Growth Rate Est. (year over year) +1.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.03 +23.52%
on 11/18/24
35.25 -36.82%
on 10/24/24
-12.88 (-36.64%)
since 10/22/24
3-Month
18.03 +23.52%
on 11/18/24
40.70 -45.28%
on 09/13/24
-15.02 (-40.28%)
since 08/22/24
52-Week
13.36 +66.69%
on 11/28/23
41.31 -46.09%
on 08/14/24
+8.07 (+56.83%)
since 11/22/23

Most Recent Stories

More News
Anaptys Announces Participation in November and December Investor Conferences

ANAB : 22.27 (+5.20%)
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

ANAB : 22.27 (+5.20%)
Why AnaptysBio Was Such a Healthy Stock This Week

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.

ANAB : 22.27 (+5.20%)
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

A powerfully bullish new analyst take on the company helped it rally on the market.

WFC : 75.96 (+1.51%)
LLY : 748.01 (-0.25%)
ANAB : 22.27 (+5.20%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 605.92 (+1.54%)
ABBV : 176.95 (+3.04%)
ABCL : 2.76 (+1.47%)
ALNY : 244.89 (-0.77%)
AMGN : 294.53 (+1.60%)
ANAB : 22.27 (+5.20%)
AZN : 65.63 (+2.13%)
BMY : 58.87 (+1.10%)
INCY : 71.72 (+1.89%)
REGN : 738.00 (-0.87%)
VIE : 53.01 (unch)
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3...

ANAB : 22.27 (+5.20%)
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...

ANAB : 22.27 (+5.20%)
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies...

ANAB : 22.27 (+5.20%)
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3...

ANAB : 22.27 (+5.20%)
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and...

ANAB : 22.27 (+5.20%)

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 24.55
2nd Resistance Point 23.46
1st Resistance Point 22.87
Last Price 22.27
1st Support Level 21.19
2nd Support Level 20.10
3rd Support Level 19.51

See More

52-Week High 41.31
Fibonacci 61.8% 30.63
Fibonacci 50% 27.33
Fibonacci 38.2% 24.04
Last Price 22.27
52-Week Low 13.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar